Research line

GLP-1 Mexico

GLP-1 analogs and incretin triagonists for research on glycemic control and satiety.

GLP-1 analogs are the most studied family in recent metabolic research. Semaglutide selectively activates the GLP-1R receptor; Tirzepatide adds GIP agonism; and Retatrutide is an experimental tri-agonist on GLP-1, GIP and glucagon.

Retatrutide, Semaglutide and Tirzepatide — the most-studied incretin analogs today.

Lyophilized vial of Retatrutide 10mg — triple-agonist GLP-1 research peptide for weight-management studies In stock

Retatrutide 10 mg

Lyophilized vial 10 mg

The Triple Agonist

$2,070MXN
Lyophilized vial of Semaglutide 5mg — GLP-1 research peptide for weight-control studies in Mexico In stock

Semaglutide 5 mg

Lyophilized vial 5 mg

GLP-1 Agonist

$2,100MXN
Lyophilized vial of Tirzepatide — dual GLP-1/GIP-agonist research peptide for metabolic studies In stock

Tirzepatide 10 mg

Lyophilized vial 10 mg

Dual GLP-1 / GIP Agonist

$1,296MXN

GLP-1R receptor

Dose-dependent activation in pancreatic cell lines.

Satiety

Preclinical models of gastric emptying and feeding behavior.

Glycemic homeostasis

Glucose-tolerance studies in animal models.